Atisama advances RB042 to phase 1 multi-dose study, names new board chair

May 15, 2026 10:25 AM

Atisama Therapeutics reported that its experimental drug RB042 has progressed to multiple ascending dose cohorts in a phase 1 clinical ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found